Published since 1955, Indian Journal of Dermatology (IJD®), (ISSN: Print- 0019-5154, Online - 1998-3611) is the oldest published journal of Dermatology in Asia and one of the oldest peer-reviewed journals dedicated to this particular discipline.

Members log-in here to access online content directly from the ISD website. The <em>International Journal of Dermatology</em> is devoted to publishing current findings and topical data on all aspects of the diagnosis and management of skin diseases.

Published monthly, the International Journal of Dermatology (IJD) is specifically designed to provide dermatologists around the world with a regular, up-to-date source of information on all aspects of the diagnosis and management of skin diseases.

e–ijd® ORIGINAL ARTICLE Effectiveness, Tolerability and Safety of Topical Clobetasol with Oral Hydroxychloroquine versus Topical Clobetasol with NBUVB Phototherapy in Unstable Vitiligo: Investigator Blind, Randomized Controlled Trial

Tranexamic acid (TXA), an anti-fibrinolytic drug has shown promising results in patients with melasma. Evidence from several clinical studies has surfaced on efficacy and tolerability of TXA in these patients. It can be used as monotherapy or adjuvant with other therapies.

DOI: 10.4103/ijd.ijd_871_22 Abstract Antibody-based therapies that inhibit pro-inflammatory cytokine signalling are commonly used in dermatology.

Skin colour usually depends upon melanin, haemoglobin, and carotenoids. Pigmentary disorders indicate an increased amount of melanin, leading to a darker colour of the skin, called hypermelanosis. Addison’s disease is a rare endocrinal disorder with …

Tofacitinib inhibits Th1-, Th2-, and Th17-associated cytokines by selectively blocking JAK1 and JAK3 receptors. We conducted a multicentric, retrospective chart analysis to study the efficacy and safety of tofacitinib in patients with moderate to severe refractory AD.

Looking for online definition of IJD or what IJD stands for? IJD is listed in the World's most authoritative dictionary of abbreviations and acronyms

To evaluate the efficacy of low-level light therapy in a helmet-like device. This study was designed as a 24-week trial with 50 participants. All participants used a helmet-shaped device emitting 630–690, 820–880, and 910–970 nm light wavelengths, for 20 minutes, daily for 24 weeks.